MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Breast Cancer Treatment Studies
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,781 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,781 works in the cohort · of 4,299,418page 16 of 56

Labels cover 13 of 2,781 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,781 of 2,781 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.
Fátima Cardoso, Aditya Bardia, Fabrice André, David W. Cescon, Heather L. McArthur, Melinda L. Telli +9 more
2019· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
26
citations
affunlabeled
Approach to inflammatory breast cancer.
Andrea Molckovsky, Barbara Fitzgerald, Orit Freedman, Ruth Heisey, Mark Clemons
2009· article· en· PubMed· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
25
citations
affunlabeled
LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)
C.H. Barrios, Nadia Harbeck, H.A. Zhang, Shigehira Saji, Ki‐Hong Jung, Roberto Hegg +14 more
2023· article· en· ESMO Open· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
25
citations
affno abstractunlabeled
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9
Jame Abraham, André Robidoux, Antoinette R. Tan, Steven Limentani, Keren Sturtz, I. Shalaby +4 more
2015· article· en· Breast Cancer Research and Treatment· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
24
citations
affaboutunlabeled
Axillary reverse mapping in breast cancer: A Canadian experience
Urve Kuusk, Nazgol Seyednejad, Elaine McKevitt, Carol Dingee, Sam M. Wiseman
2014· article· en· Journal of Surgical Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
24
citations
← previousnext →

How this was built: Screen · Findings · About